

# Mixed-Effects Pattern-Mixture Models for Incomplete Longitudinal Data

Don Hedeker  
University of Illinois at Chicago

This work was supported by National Institute of Mental Health Contract N44MH32056.

## Pattern-mixture models for missing data

*Little (1993, 1994, 1995); Hedeker & Gibbons (1997)*

- divide the subjects into groups depending on their missing data pattern
- the missing data pattern is a between-subjects variable to be used in longitudinal data analysis
- method of analysis must allow subjects to have incomplete data across time

With subjects measured at three timepoints, there are eight ( $2^3$ ) possible missing data patterns:

| pattern | group | time1 | time2 | time3 |
|---------|-------|-------|-------|-------|
| 1       |       | O     | O     | O     |
| 2       |       | O     | O     | M     |
| 3       |       | O     | M     | O     |
| 4       |       | M     | O     | O     |
| 5       |       | M     | M     | O     |
| 6       |       | O     | M     | M     |
| 7       |       | M     | O     | M     |
| 8       |       | M     | M     | M     |

where, O=observed and M=missing

Since MMM provides no data, it is ignored in the analysis

## *Representing patterns with dummy-coded variables*

| pattern | <i>D1</i> | <i>D2</i> | <i>D3</i> | <i>D4</i> | <i>D5</i> | <i>D6</i> |
|---------|-----------|-----------|-----------|-----------|-----------|-----------|
| OOO     | 0         | 0         | 0         | 0         | 0         | 0         |
| OOM     | 1         | 0         | 0         | 0         | 0         | 0         |
| OMO     | 0         | 1         | 0         | 0         | 0         | 0         |
| MOO     | 0         | 0         | 1         | 0         | 0         | 0         |
| MMO     | 0         | 0         | 0         | 1         | 0         | 0         |
| OMM     | 0         | 0         | 0         | 0         | 1         | 0         |
| MOM     | 0         | 0         | 0         | 0         | 0         | 1         |

- these dummy-coded variables represent deviations from pattern OOO
- Other coding schemes (“effect” or “sequential” coding)
- these variables are used as main effects and interactions

## *Combining patterns to increase interpretability*

- groups based on last available measurement wave:

*“recoded”*

| <i>pattern group</i> | time1 | time2 | time3 | D1 | D2 |
|----------------------|-------|-------|-------|----|----|
| 1                    | O     | M     | M     | 1  | 0  |
| 2                    | O     | O     | M     | 0  | 1  |
| 2                    | M     | O     | M     | 0  | 1  |
| 3                    | O     | O     | O     | 0  | 0  |
| 3                    | O     | M     | O     | 0  | 0  |
| 3                    | M     | O     | O     | 0  | 0  |
| 3                    | M     | M     | O     | 0  | 0  |

- grouping of complete data vs. incomplete data,

*“recoded”*

| <i>pattern</i> | <i>group</i> | time1 | time2 | time3 | D1 |
|----------------|--------------|-------|-------|-------|----|
| 1              |              | O     | O     | O     | 0  |
| 2              |              | O     | M     | M     | 1  |
| 2              |              | O     | O     | M     | 1  |
| 2              |              | M     | O     | M     | 1  |
| 2              |              | O     | M     | O     | 1  |
| 2              |              | M     | O     | O     | 1  |
| 2              |              | M     | M     | O     | 1  |

- missing vs. present at the final timepoint

*“recoded”*

| <i>pattern</i> | <i>group</i> | time1 | time2 | time3 | D1 |
|----------------|--------------|-------|-------|-------|----|
| 1              |              | O     | M     | M     | 0  |
| 1              |              | O     | O     | M     | 0  |
| 1              |              | M     | O     | M     | 0  |
| 2              |              | O     | O     | O     | 1  |
| 2              |              | O     | M     | O     | 1  |
| 2              |              | M     | O     | O     | 1  |
| 2              |              | M     | M     | O     | 1  |

*Studies with only attrition patterns - once a subject drops-out, they are gone:*

| pattern | group | time1 | time2 | time3 | D1 | D2 |
|---------|-------|-------|-------|-------|----|----|
| 1       |       | O     | M     | M     | 1  | 0  |
| 2       |       | O     | O     | M     | 0  | 1  |
| 3       |       | O     | O     | O     | 0  | 0  |

*D1* and *D2* represent differences between each of the two dropout groups and the OOO group.

## *Considerations in forming groups from missing data patterns*

- sparseness of the patterns
  - with large percentage of study completers, completers versus dropouts may be OK
- potential influence of the missing data pattern
  - intermittent missing may be random, while attrition is not
- interest in interactions
  - time interactions are not possible with OMM, MOM, & MMO patterns

# Treatment-Related Change Across Time

NIMH Schizophrenia collaborative study on treatment related changes in overall severity (IMPS item # 79). Item 79, *Severity of Illness*, was scored as:

1 = normal, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill

The experimental design and corresponding sample sizes:

---

---

| Group        | Sample size at Week |     |   |     |   |   |     | <i>completers</i> |
|--------------|---------------------|-----|---|-----|---|---|-----|-------------------|
|              | 0                   | 1   | 2 | 3   | 4 | 5 | 6   |                   |
| PLC (n=108)  | 107                 | 105 | 5 | 87  | 2 | 2 | 70  | 65%               |
| DRUG (n=329) | 327                 | 321 | 9 | 287 | 9 | 7 | 265 | 81%               |

---

---

*Drug = Chlorpromazine, Fluphenazine, or Thioridazine*

Main question of interest:

- Was there differential improvement for the drug groups relative to the control group?

## Descriptive Statistics



Observed IMPS79 Means,  $n$ , and sd

|           | <u>week 0</u> | <u>week 1</u> | <u>week 3</u> | <u>week 6</u> |
|-----------|---------------|---------------|---------------|---------------|
| placebo   | 5.35          | 4.99          | 4.74          | 4.25          |
| $n$       | 107           | 105           | 87            | 70            |
| drug      | 5.37          | 4.43          | 3.80          | 3.06          |
| $n$       | 327           | 321           | 287           | 265           |
| pooled sd | .87           | 1.23          | 1.44          | 1.48          |

Correlations:  $n = 313$  and  $321 \leq n \leq 424$

|        | <u>week 0</u> | <u>week 1</u> | <u>week 3</u> | <u>week 6</u> |
|--------|---------------|---------------|---------------|---------------|
| week 0 | 1.0           | .41           | .25           | .15           |
| week 1 | <b>.43</b>    | 1.0           | .67           | .47           |
| week 3 | <b>.29</b>    | <b>.67</b>    | 1.0           | .67           |
| week 6 | <b>.14</b>    | <b>.47</b>    | <b>.68</b>    | 1.0           |

# Plots of Means across Time by Condition



## Within-Subjects / Between-Subjects components

Within-subjects model - level 1 ( $j = 1, \dots, n_i$  obs)

$$IMPS79_{ij} = b_{0i} + b_{1i}\sqrt{Week_j} + \varepsilon_{ij}$$

Between-subjects model - level 2 ( $i = 1, \dots, N$  subjects)

$$b_{0i} = \beta_0 + \beta_2 Grp_i + v_{0i}$$

$$b_{1i} = \beta_1 + \beta_3 Grp_i + v_{1i}$$

$$\varepsilon_{ij} \sim NID(0, \sigma^2) \quad \text{level-1 residuals}$$


$$\mathbf{v}_i \sim NID(0, \boldsymbol{\Sigma}_v) \quad \text{level-2 residuals}$$

- $\beta_0$  = average week 0 IMPS79 level for PLC patients ( $Grp = 0$ )
- $\beta_1$  = average IMPS79 (sqrt) weekly change for PLC patients ( $Grp = 0$ )
- $\beta_2$  = average difference in week 0 IMPS79 for DRUG patients ( $Grp = 1$ )
- $\beta_3$  = average difference in IMPS79 (sqrt) weekly change for DRUG patients ( $Grp = 1$ )
- $v_{0i}$  = individual deviation from group intercept
- $v_{1i}$  = individual deviation from group (sqrt) weekly change

NIMH Schizophrenia Study - IMPS79 across Time: ML Estimates (se)

|                          | <i>Completers</i> |       | <i>All Subjects</i> |       |
|--------------------------|-------------------|-------|---------------------|-------|
|                          | <i>N = 335</i>    |       | <i>N = 437</i>      |       |
|                          | est.              | se    | est.                | se    |
| intercept                | 5.221             | 0.109 | 5.348               | 0.088 |
| Drug (0 = plc; 1 = drug) | 0.202             | 0.123 | 0.046               | 0.101 |
| Time (sqrt week)         | -0.393            | 0.073 | -0.336              | 0.068 |
| Drug by Time             | -0.539            | 0.083 | -0.641              | 0.078 |
| Intercept var            | 0.398             | 0.068 | 0.369               | 0.060 |
|                          | <i>sd = .63</i>   |       | <i>sd = .61</i>     |       |
| Int-Time covar           | -0.011            | 0.035 | 0.021               | 0.034 |
|                          | <i>r = -.04</i>   |       | <i>r = .07</i>      |       |
| Time var                 | 0.205             | 0.031 | 0.242               | 0.032 |
|                          | <i>sd = .45</i>   |       | <i>sd = .49</i>     |       |
| -2 log L                 | 3782.1            |       | 4649.0              |       |

# Fitted and Obs. Means across Time by Condition



$$\hat{IMPS}_{ij} = 5.35 + .05 Drug_i - .34 Time_j - .64(D_i \times T_j)$$



## Classification of Subjects based on missing-data

$$Dropout_i = \begin{cases} 0 & \text{subject measured at week 6 (last timepoint)} \\ 1 & \text{subject missing at week 6 (last timepoint)} \end{cases}$$

| Drug group | Dropout group |             | total |
|------------|---------------|-------------|-------|
|            | completer     | dropout     |       |
| placebo    | 70<br>(.65)   | 38<br>(.35) | 108   |
| drug       | 265<br>(.81)  | 64<br>(.19) | 329   |
| total      | 335           | 102         | 437   |

- Dropout not independent of Drug  $\chi_1^2 = 11.25, p < .001$
- Is dropout related to severity of illness?
- Does dropout moderate the influence of other variables' effects on severity of illness?

# Means across Time by Condition by Dropout



## Within-Subjects / Between-Subjects components

Within-subjects model - level 1 ( $j = 1, \dots, n_i$  obs)

$$IMPS79_{ij} = b_{0i} + b_{1i}\sqrt{Week_j} + \varepsilon_{ij}$$

Between-subjects model - level 2 ( $i = 1, \dots, N$  subjects)

$$b_{0i} = \beta_0 + \beta_2 Grp_i + \beta_4 Drop_i + \beta_6(G_i \times D_i) + v_{0i}$$

$$b_{1i} = \beta_1 + \beta_3 Grp_i + \beta_5 Drop_i + \beta_7(G_i \times D_i) + v_{1i}$$

$$\varepsilon_{ij} \sim NID(0, \sigma^2) \quad \text{level-1 residuals}$$

$$\mathbf{v}_i \sim NID(0, \boldsymbol{\Sigma}_v) \quad \text{level-2 residuals}$$

$$Grp_i = \begin{cases} 0 & \text{placebo} \\ 1 & \text{drug} \end{cases} \quad Drop_i = \begin{cases} 0 & \text{completer} \\ 1 & \text{dropout} \end{cases}$$

Pattern mixture model: *Dropouts vs Completers*

|  | est.   | se    | $z$   | $p <$ |
|--|--------|-------|-------|-------|
| intercept<br><i>placebo completers at week 0</i>   | 5.221  | 0.108 | 48.55 | .001  |
| Drug (0=P; 1=D)<br><i>for completers at week 0</i> | 0.202  | 0.121 | 1.67  | .10   |
| Dropout (0=N; 1=Y)<br><i>for placebo at week 0</i> | 0.320  | 0.186 | 1.72  | .09   |
| Drug by Dropout<br><i>week 0 interaction</i>       | -0.399 | 0.227 | -1.76 | .08   |
| Time (sqrt week)<br><i>for placebo completers</i>  | -0.393 | 0.076 | -5.15 | .001  |
| Drug by Time<br><i>for completers</i>              | -0.539 | 0.086 | -6.28 | .001  |
| Dropout by Time<br><i>for placebo</i>              | 0.252  | 0.159 | 1.58  | .12   |
| 3 Way  | -0.635 | 0.196 | 3.24  | .002  |

## Estimated Trends by Subgroups

Placebo Completers

$$\hat{Y} = 5.22 - .39 \textit{ Time}$$

Drug Completers

$$\hat{Y} = (5.22 + .20) - (.39 + .54) \textit{ Time} = 5.42 - .93 \textit{ Time}$$

$\Rightarrow$  *difference in slope = -.54*

Placebo Dropouts

$$\hat{Y} = (5.22 + .32) - (.39 + .25) \textit{ Time} = 5.54 - .14 \textit{ Time}$$

Drug Dropouts



$$\begin{aligned} \hat{Y} &= (5.22 + .20 + .32 - .40) - (.39 + .54 - .25 + .64) \textit{ Time} \\ &= 5.34 - 1.32 \textit{ Time} \end{aligned}$$

$\Rightarrow$  *difference in slope = -1.17*

$\Rightarrow$  *difference in slope difference = -.64*

*degree that Drug by Time interaction varies by Dropout*

# Obs & Est Means across Time by Cond by Drop



## Pattern-mixture averaged results (Little, 1995)

- Obtained averaging over missing-data patterns
  - *e.g.*, completers and dropouts
- Uses sample proportions as estimates of missing-data pattern proportions
- Can use Delta Method to obtain standard errors
  - uncertainty in model estimates
  - uncertainty in using sample proportions as estimates
- Depends on “model” for missing-data patterns
  - *e.g.*, completer versus dropout status varies by tx

### Completer

*placebo*      *70/108*

*drug*          *265/329*

**335/437**

### Dropout

*placebo*      *38/108*

*drug*          *64/329*

**102/437**

## Pattern-mixture averaged results

$$\hat{\beta} = \hat{\pi}_c \hat{\beta}_c + \hat{\pi}_d \hat{\beta}_d$$

or

$$\hat{\beta} = (1 - \hat{\pi}_d) \hat{\beta}_c + \hat{\pi}_d \hat{\beta}_d = \hat{\beta}_c + \hat{\pi}_d (\hat{\beta}_d - \hat{\beta}_c) = \hat{\beta}_c + \hat{\pi}_d \hat{\beta}_\Delta$$

note:

- $\hat{\beta}_c$  correspond to the coefficients in the current model formulation not involving dropout (*i.e.*, intercept, drug, time, drug by time)
- $(\hat{\beta}_d - \hat{\beta}_c) = \hat{\beta}_\Delta$  correspond to the dropout-related coefficients in the current model formulation (*i.e.*, dropout, dropout by drug, dropout by time, dropout by drug by time)
- $\hat{\pi}_d$  is the sample proportion of dropouts

$\Rightarrow$  averaged estimates are simple linear combinations of model estimates

## Placebo Intercept

$$\frac{335}{437}(5.22) + \frac{102}{437}(5.22 + 0.32) = 5.22 + (.233)(0.32) = 5.30$$

*Completers*      *Dropouts*

## Placebo Time effect

$$\frac{335}{437}(-0.39) + \frac{102}{437}(-0.39 + 0.25) = -0.39 + (.233)(0.25) = -0.33$$

*Completers*      *Dropouts*

## Drug Intercept difference

$$\frac{335}{437}(0.20) + \frac{102}{437}(0.20 - 0.40) = 0.20 + (.233)(-0.40) = 0.11$$

*Completers*      *Dropouts*

## Drug Time difference

$$\frac{335}{437}(-0.54) + \frac{102}{437}(-0.54 - 0.64) = -0.54 + (.233)(-0.64) = -0.69$$

*Completers*      *Dropouts*

**Delta Method** for estimating asymptotic variance of averaged estimates

$$\hat{\beta} = \hat{\beta}_c + \hat{\pi}_d \hat{\beta}_\Delta$$

$$\hat{V}(\hat{\beta}) = \begin{bmatrix} \frac{\partial \hat{\beta}}{\partial \hat{\beta}_c} & \frac{\partial \hat{\beta}}{\partial \hat{\beta}_\Delta} & \frac{\partial \hat{\beta}}{\partial \hat{\pi}_d} \end{bmatrix} \begin{bmatrix} \hat{V}(\hat{\beta}_c) & \hat{C}(\hat{\beta}_c, \hat{\beta}_\Delta) & 0 \\ \hat{C}(\hat{\beta}_c, \hat{\beta}_\Delta) & \hat{V}(\hat{\beta}_\Delta) & 0 \\ 0 & 0 & \hat{V}(\hat{\pi}_d) \end{bmatrix} \begin{bmatrix} \frac{\partial \hat{\beta}}{\partial \hat{\beta}_c} \\ \frac{\partial \hat{\beta}}{\partial \hat{\beta}_\Delta} \\ \frac{\partial \hat{\beta}}{\partial \hat{\pi}_d} \end{bmatrix}$$

where

$$\frac{\partial \hat{\beta}}{\partial \hat{\beta}_c} = 1 \quad \frac{\partial \hat{\beta}}{\partial \hat{\beta}_\Delta} = \hat{\pi}_d \quad \frac{\partial \hat{\beta}}{\partial \hat{\pi}_d} = \hat{\beta}_\Delta$$

Thus,

$$\hat{V}(\hat{\beta}) = \hat{V}(\hat{\beta}_c) + \hat{\pi}_d^2 \hat{V}(\hat{\beta}_\Delta) + 2\hat{\pi}_d \hat{C}(\hat{\beta}_c, \hat{\beta}_\Delta) + \hat{\beta}_\Delta^2 \hat{V}(\hat{\pi}_d)$$

Note, under marginal model for completion (*i.e.*, = binomial( $\pi_c$ ))

$$\begin{aligned} \hat{V}(\hat{\pi}_d) &= \hat{\pi}_d(1 - \hat{\pi}_d)/N \\ &= (n_d/N)(n_c/N)/N = \frac{n_d n_c}{N^3} \end{aligned}$$

## Standard Errors for Averaged Estimates

$$\begin{aligned}\hat{V}(\hat{\boldsymbol{\beta}}) &= \hat{V}(\hat{\boldsymbol{\beta}}_c) + \hat{\pi}_d^2 \hat{V}(\hat{\boldsymbol{\beta}}_\Delta) + 2\hat{\pi}_d \hat{C}(\hat{\boldsymbol{\beta}}_c, \hat{\boldsymbol{\beta}}_\Delta) + \hat{\boldsymbol{\beta}}_\Delta^2 \hat{V}(\hat{\pi}_d) \\ &= \hat{V}(\hat{\boldsymbol{\beta}})_F + \frac{n_d n_c}{N^3} \hat{\boldsymbol{\beta}}_\Delta^2\end{aligned}$$

where,  $\hat{V}(\hat{\boldsymbol{\beta}})_F$  is the variance treating the sample proportions as known, *i.e.*, the square of the standard error one gets using

$$\hat{\boldsymbol{\beta}} = \hat{\boldsymbol{\beta}}_c + \hat{\pi}_d \hat{\boldsymbol{\beta}}_\Delta$$

and not taking into account the fact that  $\pi_d$  is estimated (*i.e.*, this is obtained using methods that yield linear combinations of estimates and their associated standard errors)

$\Rightarrow$  simple augmentation of  $\hat{V}(\hat{\boldsymbol{\beta}})_F$  to get correct standard errors

Calculation of  $\hat{V}(\hat{\tilde{\beta}}) = \hat{V}(\hat{\tilde{\beta}})_F + \frac{n_d n_c}{N^3} \hat{\beta}_\Delta^2$

| parameter          | $\hat{\tilde{\beta}}$ | $\hat{V}(\hat{\tilde{\beta}})_F$ | $\hat{\beta}_\Delta$ | Augment | $\hat{V}(\hat{\tilde{\beta}})$ | SE    |
|--------------------|-----------------------|----------------------------------|----------------------|---------|--------------------------------|-------|
| intercept          | 5.2958                | $(.0898)^2 = .00806$             | .3203                | .000042 | .00810                         | .0900 |
| time               | -.3346                | $(.0670)^2 = .00449$             | .2517                | .000026 | .00452                         | .0672 |
| drug               | .1086                 | $(.1029)^2 = .01059$             | -.3987               | .000065 | .01066                         | .1032 |
| drug $\times$ time | -.6868                | $(.0776)^2 = .00602$             | -.6348               | .000165 | .00619                         | .0786 |

Augment =  $\frac{n_d n_c}{N^3} \hat{\beta}_\Delta^2$  , here,  $\frac{n_d n_c}{N^3} = \frac{102 \times 335}{(437)^3} = .00040945$

## Pattern-mixture averaged results - using drug-stratified proportions

### Placebo Intercept

$$\frac{70}{108}(5.22) + \frac{38}{108}(5.22 + 0.32) = 5.22 + (.352)(0.32) = 5.33$$

*Completers*      *Dropouts*

### Placebo Time effect

$$\frac{70}{108}(-0.39) + \frac{38}{108}(-0.39 + 0.25) = -0.39 + (.352)(0.25) = -0.30$$

*Completers*      *Dropouts*

### Drug Intercept difference

$$\frac{265}{329}(0.20) + \frac{64}{329}(0.20 - 0.40) = 0.20 + (.195)(-0.40) = 0.12$$

*Completers*      *Dropouts*

### Drug Time difference

$$\frac{265}{329}(-0.54) + \frac{64}{329}(-0.54 - 0.64) = -0.54 + (.195)(-0.64) = -0.66$$

*Completers*      *Dropouts*

Calculation of  $\hat{V}(\hat{\beta}) = \hat{V}(\hat{\beta})_F + \frac{n_d n_c}{N^3} \hat{\beta}_\Delta^2$

| parameter          | $\hat{\beta}$ | $\hat{V}(\hat{\beta})_F$ | $\hat{\beta}_\Delta$ | Augment | $\hat{V}(\hat{\beta})$ | SE    |
|--------------------|---------------|--------------------------|----------------------|---------|------------------------|-------|
| intercept          | 5.3337        | $(.0879)^2 = .00773$     | .3203                | .000217 | .00795                 | .0891 |
| time               | -.3048        | $(.0698)^2 = .00487$     | .2517                | .000134 | .00500                 | .0707 |
| drug               | .1241         | $(.1043)^2 = .01088$     | -.3987               | .000076 | .01096                 | .1047 |
| drug $\times$ time | -.6621        | $(.0772)^2 = .00596$     | -.6348               | .000192 | .00615                 | .0784 |

Augment =  $\frac{n_d n_c}{N^3} \hat{\beta}_\Delta^2$  , where

$$\frac{n_d n_c}{N^3} = \frac{38 \times 70}{(108)^3} = .00211159 \text{ for placebo}$$

$$\frac{n_d n_c}{N^3} = \frac{64 \times 265}{(329)^3} = .00047625 \text{ for drug}$$

NIMH Schizophrenia Study: Severity across Time  
MML Estimates (se) *random intercept and slope models*

|                 | <i>Completers</i><br><i>N = 335</i> | <i>All cases</i><br><i>N = 437</i> | <i>Pattern</i><br><i>mixture</i><br><i>N = 437</i> |
|-----------------|-------------------------------------|------------------------------------|--|
| intercept       | 5.221<br>(.109)                     | 5.348<br>(.088)                    | 5.334<br>(.089)                                    |
| Drug (0=P; 1=D) | 0.202<br>(.123)                     | 0.046<br>(.101)                    | 0.124<br>(.105)                                    |
| Time (sqrt wk)  | -0.393<br>(.073)                    | -0.336<br>(.068)                   | -0.305<br>(.071)                                   |
| Drug by Time    | -0.539<br>(.083)                    | -0.641<br>(.078)                   | -0.662<br>(.078)                                   |

## Conclusions

- Mixed-effects models useful for incomplete longitudinal data
  - can handle subjects measured incompletely or at different timepoints
  - missing data assumed MAR
    - \* dependent on covariates *and*
    - \* available data on dependent variable
- Mixed-effects pattern-mixture models maybe more useful
  - adds missing-data pattern as between-subjects factor
  - assesses degree to which “missingness” influences (available) outcomes
  - assesses degree to which “missingness” interacts with model terms
    - \* intervention group
    - \* intervention group by time

⇒ Does not invent data, maximizes information obtained from *available* data